Topic: profits

Celgene boosts Q2 sales by whopping 22%; Shire raises guidance, citing Vyvanse, Firazyr sales; Amgen files for new Kyprolis use;

Thursday, July 23, 2015

@FiercePharma: NIAID scientists one step closer to 'universal' flu vaccine. More | Follow @FiercePharma @CarlyHFierce: Earnings season is better than Christmas. I mean, I actually like most...

Gene study boosts hopes for Merck's Zetia; Sun profits lag estimates; Stada buyout gains offset sliding Russia sales;

by Tracy Staton

Thursday, November 13, 2014

@FiercePharma: Merck JV signs on Bangladeshi firms to speed low-cost cholera candidate. More | Follow @FiercePharma @EricPFierce: Cadilia gets slapped with #FDA warning for not following up on...

HIV drugmakers extend discounts for cash-strapped AIDS programs; Teva profits, sales drop on fewer generic launches;

by Tracy Staton

Thursday, August 1, 2013

@FiercePharma: Pharma tension rises in China as officials fine J&J, visit Sanofi; AZ chief anticipates pricing moves. News | Follow @FiercePharma @CarlyHFierce: Price controls in India...

Celgene, Elan settle Abraxane case for $78M; Health groups ask Novartis to back off Gleevec patent;

by Tracy Staton

Friday, February 25, 2011

@FiercePharma: AZ's dental unit attracts a slew of suitors. Story | Follow @FiercePharma > Celgene has agreed to pay Elan $78 million to settle a patent infringement lawsuit over the Celgene

Celgene drug could triple sales on new study

by Tracy Staton

Monday, November 30, 2009

Celegene could get a big boost from new data set to be reported next week. Revlimid, its best-selling multiple myeloma pill, could emerge as a first-line treatment rather than Johnson & Johnson's